stella
beta
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome — Stella
Home
/
Monoclonal Gammopathy of Undetermined Significance (MGUS)
/
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
View on ClinicalTrials.gov
Recruiting
Back to Monoclonal Gammopathy of Undetermined Significance (MGUS) trials
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Trial locations
(7 sites)
United States
Dana-Farber Cancer Institute, Boston, Massachusetts
Dana Farber Cancer Institute at St. Elizabeth's, Brighton, Massachusetts
Dana Farber Cancer Institute at Merrimack Valley, Methuen, Massachusetts
Dana Farber Cancer Institute at Milford Regional Medical Center, Milford, Massachusetts
Dana Farber Cancer Institute at South Shore, Weymouth, Massachusetts
West Michigan Cancer Center, Kalamazoo, Michigan
Dana Farber/New Hampshire Oncology-Hematology, Londonderry, New Hampshire
Follow this trial
Get notified in plain English when this trial's status changes. No account required.
Follow